Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells

PURPOSE: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Amin, Cao, Weiya, Liu, Xueke, Zhang, Yinci, Ma, Yongfang, Xu, Ruyue, Zhang, Rongbo, Liu, Xinkuang, Zhou, Shuping, Wang, Ruikai, Liu, Jiachang, Tang, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185832/
https://www.ncbi.nlm.nih.gov/pubmed/32342201
http://dx.doi.org/10.1007/s00432-020-03228-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185832/
https://www.ncbi.nlm.nih.gov/pubmed/32342201
http://dx.doi.org/10.1007/s00432-020-03228-4

Ejemplares similares